Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Entacapone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Entacapone | DRUG | - |
Inclusion Criteria: * Attended the Phase IIb study * Able to fill out the patient diary Exclusion Criteria: * Serious heart, pulmonary, renal, hepatic or gastrointestinal disease * Dementia symptoms * Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may a...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
Entacapone is an investigational small molecule being studied in Parkinson's Disease, specifically for patients experiencing end-of-dose wearing-off. It is being developed by Novartis AG and is currently in Phase 2 clinical development. Wearing-off refers to the return of Parkinson's symptoms between doses of levodopa therapy.
Entacapone targets COMT, which stands for catechol-O-methyltransferase. It is classified as a COMT inhibitor. By targeting this enzyme, the drug is designed to affect the metabolism of dopamine-related compounds in the body. This mechanism is relevant to its study in Parkinson's Disease patients with end-of-dose wearing-off.
Entacapone is being developed by Novartis AG, which trades under the ticker NVS. The company is the sponsor associated with the clinical development of this COMT inhibitor for Parkinson's Disease. Novartis AG is a multinational pharmaceutical company headquartered in Switzerland.
Entacapone is in Phase 2 clinical development for Parkinson's Disease. It is an investigational small molecule and is not described as approved. The Phase 2 program includes one completed trial evaluating the drug in patients with Parkinson's Disease who experience end-of-dose wearing-off.
Entacapone has been studied in the Phase 2 trial NCT00237263, titled an extension study of Entacapone in patients with Parkinson's Disease with end-of-dose wearing-off. The trial is completed and enrolled 285 participants. It was conducted in the United States and included patients aged 20 years and older of all sexes.
Yes, Entacapone is classified as a COMT inhibitor. Its molecular target is COMT, or catechol-O-methyltransferase. This target class places it among compounds designed to inhibit that enzyme. It is being studied as a small molecule in Phase 2 development for Parkinson's Disease, specifically for patients with end-of-dose wearing-off.